Skip to main content
PEPTARA LABS
Get Started

Reference

Peptide Glossary: 108 Research and Safety Terms

Published by · Updated · How we research and check our pages

This peptide glossary from Peptara Labs (peptaralabs.io) defines the terms used across peptide research and safety, each with its own link. Find a term by letter in the A to Z index, or browse the six topics below. Where the site has a full page on a term, its definition links to it. Every section ends with its sources, all from regulators, the National Library of Medicine and peer-reviewed journals. Educational only; not medical advice.

Six categories

  • Pharmacology: 25 terms (agonist, half-life, bioavailability, etc.)
  • Units and measures: 9 terms (mcg, mg, IU, U-100 syringe, ED50, etc.)
  • Reconstitution: 14 terms (bac water, insulin syringe, lyophilized, etc.)
  • Safety: 25 terms (adverse event, CTCAE grading, MTC, MEN2, etc.)
  • Regulatory: 15 terms (FDA-approved, Phase 1-4, research compound, etc.)
  • Mechanism: 20 terms (GLP-1, GIP, GHRH, thymosin beta-4, etc.)

Pharmacology

25 terms in this category.

Agonist
A compound that binds to a receptor and activates it. Most peptide drugs are receptor agonists. Contrast antagonist.
Antagonist
A compound that binds to a receptor and blocks activation.
Partial agonist
A compound that binds and activates a receptor but with reduced maximal effect compared to a full agonist.
Inverse agonist
A compound that binds and produces the opposite biological effect of an agonist.
Receptor
A protein on or in a cell that recognizes a specific molecule and triggers a downstream signal.
GLP-1 receptor
The receptor activated by glucagon-like peptide-1 and by GLP-1 class drugs (semaglutide, tirzepatide, retatrutide).
Half-life
How long the blood level of a compound takes to drop by half. After 4 to 5 half-lives, 94 to 97 percent of it is gone, and repeated exposure levels off over about the same time. FDA labels put semaglutide at about 1 week and tirzepatide at about 5 days; for BPC-157, a 2022 study in rats and dogs measured less than 30 minutes. How half-life is measured, and why it differs so much from one compound to the next.
Cmax
The peak plasma concentration of a compound after administration.
Tmax
The time after administration at which Cmax is reached.
AUC
Area under the plasma concentration vs time curve. A measure of total drug exposure.
Bioavailability
The fraction of an administered dose that reaches systemic circulation unchanged.
First-pass metabolism
Hepatic metabolism that reduces oral drug bioavailability. Peptides are typically injected to bypass this.
Subcutaneous
Subcutaneous (subQ) means into the fatty layer just below the skin. Many approved peptide drugs, semaglutide among them, are labeled for subcutaneous use.
Intramuscular
Intramuscular (IM) means into muscle tissue, a separate route from subcutaneous.
Pharmacokinetics
Pharmacokinetics (PK) is the study of how a compound is absorbed, distributed, metabolized, and excreted.
Pharmacodynamics
Pharmacodynamics (PD) is the study of what a compound does to the body, including potency and effect duration.
Titration
A trial design in which the amount given is raised in planned steps, so side effects can be watched as exposure grows. In a forced titration study, every participant moves up through the same rising steps in a set order, not a random one. In GLP-1 class trials, most stomach side effects appeared during the step-up period and eased after.
Steady state
The point at which drug input equals drug elimination, producing stable plasma levels. Typically reached after 4 to 5 half-lives.
Depot formation
Localized accumulation of injected drug that slowly releases over time, extending half-life.
Secretagogue
A compound that triggers release of an endogenous hormone. Ipamorelin is a GH secretagogue. What a peptide secretagogue is, with the research behind the term.
Analog
A structurally modified compound retaining the parent's core activity. Semaglutide is a GLP-1 analog.
Fragment
A shorter piece of a larger peptide that keeps some of the parent activity. Teriparatide, for example, matches the first 34 of the 84 amino acids of human parathyroid hormone and binds the same receptors. BPC-157 is a 15-amino-acid fragment of BPC, a peptide found in human gastric juice.
kDa
Kilodalton, a unit of molecular mass equal to 1,000 daltons. There is no single size line between peptides and proteins: US FDA rules count a chain of more than 40 amino acids as a protein, so insulin, at 51 amino acids and about 5.8 kDa, is a protein. For scale, BPC-157 is about 1.4 kDa and semaglutide about 4.1 kDa.
Pulsatile
Pulsatile release means hormone is secreted in bursts (e.g., GH at night) rather than continuously.
Tachyphylaxis
A response that weakens quickly when a drug is given again and again in a short time.

Sources for this section: StatPearls (NCBI Bookshelf), Elimination Half-Life of Drugs, 2025; Ozempic prescribing information (DailyMed); Mounjaro prescribing information (DailyMed); Forteo prescribing information (DailyMed); Humulin R prescribing information (DailyMed); He and colleagues, Frontiers in Pharmacology 2022 (PMID 36588717); ICH E4 guideline, FDA 1994; FDA final rule defining a protein, Federal Register 2020; MeSH record for BPC 157 (National Library of Medicine).

Units and measures

9 terms in this category.

mcg
Microgram, one millionth of a gram, which is one thousandth of a milligram. The abbreviation is easy to misread: the FDA warns that mcg can be taken for mg, a thousandfold error, so some labels spell the word out.
mg
Milligram, one thousandth of a gram. For approved peptide medicines in the EU, the stated strength is the mass of the peptide itself, not counting salt or counter-ion. Synthetic peptide powders usually also hold acetate and some water, which is why a certificate can list net peptide content apart from the powder weight.
IU
International unit. A potency-based unit; conversion to mg varies by compound. Not interchangeable with syringe units.
U-100 syringe
An insulin syringe whose marks are scaled for U-100 insulin. The marks measure volume, not peptide. A U-100 units chart that converts marks to mL is published on peptidesvietnam.com.
U-40 syringe
An insulin syringe scaled for U-40 insulin, so each mark holds more liquid than a U-100 mark. Less common.
U-500 syringe
A syringe made for concentrated U-500 insulin. Not standard for reconstituted peptide vials.
Units
The volume marks on an insulin syringe. Most insulin syringes are scaled for U-100 insulin, where one milliliter holds one hundred units, so each small mark is one hundredth of a milliliter of liquid. The marks measure volume, not how much peptide the liquid holds, and they are not the same as IU. Syringe units compared with milligrams, with the arithmetic worked through.
ED50
In a study, the amount that produced half of the largest effect measured. A potency comparison, not a human dose.
ED90
In a study, the amount that produced 90 percent of the largest effect measured. Also a potency comparison.

Sources for this section: NIST, Metric (SI) Prefixes; FDA, A Microgram of Prevention is Worth a Milligram of Cure, 2024; MedlinePlus (National Library of Medicine), Giving an insulin injection; European Medicines Agency, synthetic peptides guideline, 2025; Humulin R U-500 prescribing information (DailyMed).

Reconstitution

14 terms in this category.

Bacteriostatic water
Sterile water for injection with benzyl alcohol added as a preservative, usually 0.9 percent. It comes in a multiple-dose vial so it can be drawn from more than once, and its label says it is for diluting or dissolving drugs. The same label warns that benzyl alcohol must not be used in newborns. More on bacteriostatic water, including what the benzyl alcohol is for.
Benzyl alcohol
The preservative in bacteriostatic water. Inhibits bacterial growth in multi-use vials.
Vial
A small glass bottle with a rubber stopper, sealed under vacuum. Most peptides ship as a lyophilized powder in vials.
Diluent
The liquid used to dissolve a lyophilized peptide. Bacteriostatic water is the standard diluent.
Reconstitution
Dissolving a freeze-dried (lyophilized) powder in a sterile liquid, called a diluent, such as bacteriostatic water. Many peptides are freeze-dried because they are unstable in water, and the FDA describes the process as removing water from a frozen product under vacuum. Once mixed, the solution has its own, shorter shelf life. How reconstitution is done, from the water to a clear solution.
Swirl
A gentle circular motion that dissolves a freeze-dried powder in its diluent. Reconstitution guides describe it in place of shaking, which can foam the solution.
Recon volume
The volume of bacteriostatic water added to a vial. It sets the concentration of the mixed vial. The reconstitution calculator works out the concentration for any vial and volume.
27G needle
27-gauge needle. In needle sizing, a higher gauge number means a thinner needle.
29G needle
29-gauge needle, thinner than a 27-gauge one.
31G needle
31-gauge needle, among the thinnest needle sizes made.
Insulin syringe
A small syringe with a short, fine needle and volume marks. Sizes are named by how much liquid the barrel holds.
0.5 mL syringe
The smaller of the two common insulin syringe sizes.
1 mL syringe
The larger of the two common insulin syringe sizes.
Lyophilized
Freeze-dried. Most peptide vials ship as a lyophilized powder cake that requires reconstitution. What a lyophilized peptide is, and how the dry vial is stored before mixing.

Sources for this section: Bacteriostatic Water for Injection, USP, FDA-approved labeling (DailyMed); FDA, Lyophilization of Parenteral, inspection guide; European Medicines Agency, synthetic peptides guideline, 2025.

Safety

25 terms in this category.

Adverse event
Adverse event (AE). Any unfavorable medical occurrence during drug use, whether causally related or not.
Serious adverse event
Serious adverse event (SAE). An AE that results in death, hospitalization, persistent disability, or is life-threatening.
CTCAE grading
Common Terminology Criteria for Adverse Events. A 5-grade severity scale (Grade 1 mild to Grade 5 death) used in oncology and increasingly in peptide trials.
Contraindication
A condition or factor that makes a drug inappropriate to use.
Absolute contraindication
A condition under which a drug must never be used. Example: Wilson disease for GHK-Cu.
Relative contraindication
A condition under which a drug should be used with caution or monitoring.
Black-box warning
The strongest safety warning the FDA puts on a prescription drug label, printed inside a box; the FDA calls it a boxed warning. It can rest on animal findings when human data are missing, and more than 400 medicines carry one. Semaglutide and tirzepatide carry one for thyroid C-cell tumors seen in rodents; whether this happens in people is unknown.
Nausea
A sick feeling in the stomach, often with an urge to vomit. It was the most common adverse event in the large Phase 3 weight trials of drugs that act on the GLP-1 receptor, such as STEP 1 and SURMOUNT-1. Most cases were mild to moderate and came early, while the amount given was being stepped up.
Emesis
Vomiting. A frequent GI adverse event on GLP-1 class drugs.
Lipohypertrophy
A lump of fatty tissue that can form where injections are given again and again in the same spot.
Injection-site reaction
Redness, itching, swelling or pain where an injection was given.
Erythema
Redness of the skin, often at an injection site.
Pruritus
Itching, often at an injection site or as part of a systemic reaction.
Hypoglycemia
Low blood glucose. A risk on GLP-1 class drugs especially when combined with insulin or sulfonylureas.
Hyperglycemia
Elevated blood glucose.
Pancreatitis
Inflammation of the pancreas. A rare reported adverse event on GLP-1 class drugs.
Gastroparesis
Delayed gastric emptying. Reported with semaglutide, less common with tirzepatide.
MTC
Medullary thyroid carcinoma. A rare thyroid cancer linked to C-cell tumors. Black-box concern for GLP-1 class drugs.
MEN2
Multiple endocrine neoplasia type 2. A hereditary syndrome that includes risk of MTC. Absolute contraindication for tirzepatide and retatrutide.
Retinopathy
Damage to the retinal blood vessels. Risk in diabetics on GH-axis peptides; semaglutide also carries a documented retinopathy signal in SUSTAIN-6.
IGF-1
Insulin-like growth factor 1, a 70-amino-acid hormone made mainly in the liver when growth hormone acts on it. Growth hormone levels swing through the day while IGF-1 stays steadier, which is why studies of GH-axis peptides such as CJC-1295 and ipamorelin measure IGF-1 as the marker.
Water retention
Edema. A common reported effect on GH-axis peptides, typically transient.
Wilson disease
A genetic disorder of copper metabolism. Absolute contraindication for GHK-Cu and any copper-containing peptide.
Angiogenesis
Formation of new blood vessels. Pro-angiogenic activity in tissue-repair peptides raises a theoretical (not human-confirmed) tumor concern.
Pharmacovigilance
Ongoing safety monitoring of a drug after release. FDA-approved drugs report through MedWatch; research compounds rely on user-reported registries.

Sources for this section: 21 CFR 201.57(c)(1), boxed warning (eCFR); StatPearls (NCBI Bookshelf), Box Warning, 2023; Ozempic prescribing information (DailyMed); Wegovy prescribing information (DailyMed); Mounjaro prescribing information (DailyMed); Zepbound prescribing information (DailyMed); Increlex prescribing information (DailyMed); Wilding and colleagues, STEP 1 trial, New England Journal of Medicine 2021 (PMID 33567185); Jastreboff and colleagues, SURMOUNT-1 trial, New England Journal of Medicine 2022 (PMID 35658024); SURMOUNT-1 results, ClinicalTrials.gov NCT04184622; MedlinePlus, IGF-1 test.

Regulatory

15 terms in this category.

FDA-approved
Approved by the US Food and Drug Administration for a specific use, once the agency decides the benefits of the drug outweigh its risks for that use. With rare exceptions, new drugs must be approved before they are sold or shipped between states. The FDA does not approve compounded drugs, and clearance is a separate route used for medical devices. Examples: Mounjaro (tirzepatide), Ozempic (semaglutide). FDA-approved peptides, listed by drug class with the source for every figure.
Phase 1
First-in-human safety trials, typically n=20 to 100, healthy volunteers.
Phase 2
Dose-finding and efficacy trials, typically n=100 to 500, target population.
Phase 3
Pivotal efficacy and safety trials, typically n=1,000 to 10,000+. Required for FDA approval.
Phase 4
Post-marketing surveillance after a drug is approved.
IND
Investigational New Drug application, the FDA filing that lets a sponsor ship an unapproved drug to trial sites so human trials can begin. It covers animal pharmacology and toxicology, manufacturing, and the trial protocols and investigators. After filing, the sponsor waits 30 calendar days before starting, and the FDA can stop a trial with a clinical hold.
NDA
New Drug Application, the filing through which a sponsor formally asks the FDA to approve a new drug for sale in the US. The animal and human data gathered under the IND become part of it, and reviewers weigh whether the drug is safe and effective for its proposed use and whether its benefits outweigh its risks. The FDA aims to act within 10 months on a standard review and 6 months on a priority review.
503A
A US compounding pharmacy that prepares patient-specific compounded drugs. Was the source of compounded semaglutide during shortages.
503B
A US outsourcing facility that prepares larger-batch compounded drugs.
Research compound
A peptide intended for laboratory research only and not approved for human consumption. BPC-157, TB-500, KLOW Combo, MOTS-c, SLU-PP-332, and others fall in this category. Where research peptides are legal, country by country.
Prescription
Drugs that require a licensed prescriber's authorization. All FDA-approved peptides are prescription only.
COA
Certificate of Analysis, a document that lists the tests run on a batch, the pass limits and the actual results. Under international manufacturing guidance it is dated, signed by the quality unit and issued for one batch; when someone other than the maker reissues it, it must name the lab that did the testing. Peptara Labs publishes the certificate for each released batch on its certificates page. How to read a certificate of analysis, one line at a time.
HPLC
High-performance liquid chromatography. The standard purity test for peptides. How peptide purity is checked, and what an HPLC result can and cannot show.
Mass spectrometry
Mass spectrometry, a lab method that identifies a molecule from its mass and the way it breaks into fragments. For peptides it confirms identity by measuring molecular mass, and a tandem version (LC-MS/MS) can confirm the amino acid sequence. European medicines guidance lists it among the standard identity tests for synthetic peptides.
NMR
Nuclear magnetic resonance. Confirms peptide structure.

Sources for this section: FDA, Investigational New Drug Application (IND); FDA, New Drug Application (NDA); FDA, Priority Review; FDA, Is It Really FDA Approved?; FDA, ICH Q7 Good Manufacturing Practice guidance, 2016; European Medicines Agency, synthetic peptides guideline, 2025.

Mechanism

20 terms in this category.

GLP-1
Glucagon-like peptide-1, a gut hormone about 30 amino acids long that is released after eating. As an incretin it raises insulin release only when glucose is high, lowers glucagon and slows stomach emptying. Natural GLP-1 lasts about 2 minutes in the blood; semaglutide shares 94 percent of its sequence but lasts about a week. GLP-1 receptor agonists explained, from receptor to approved drugs.
GIP
Glucose-dependent insulinotropic polypeptide, a 42-amino-acid hormone released from the upper small intestine. It was the first incretin hormone found, and after a meal GIP and GLP-1 add about equally to the rise in insulin. Tirzepatide and retatrutide activate the GIP receptor in addition to GLP-1.
Glucagon
A 29-amino-acid hormone made in the pancreas that raises blood glucose by making the liver release stored glucose. GLP-1 lowers glucagon release while GIP raises it. Retatrutide is a glucagon receptor agonist in addition to GLP-1 and GIP.
GH
Growth hormone (somatotropin), a 191-amino-acid protein made in the front lobe of the pituitary gland. GHRH, somatostatin and ghrelin control its release, so it comes in pulses that change hour to hour and a single blood reading says little; studies use steadier markers such as IGF-1. GH-axis peptides act on it indirectly.
GHRH
Growth-hormone-releasing hormone. A hypothalamic peptide that triggers GH release. CJC-1295 is a GHRH analog.
GHRP
Growth-hormone-releasing peptide. A class of synthetic peptides that mimic ghrelin to trigger pulsatile GH release. Ipamorelin is a GHRP. The GHRP family, member by member, with where each one stands with the FDA.
mTOR
Mechanistic target of rapamycin. A central regulator of cell growth and metabolism. Inhibition is linked to longevity research.
AMPK
AMP-activated protein kinase. A cellular energy sensor activated by exercise and by some peptides (notably MOTS-c).
Mitochondrial biogenesis
The formation of new mitochondria within cells. Driven by MOTS-c, exercise, and some pharmacological agents.
Thymosin beta-4
A 43-amino-acid peptide involved in actin sequestration, angiogenesis, and tissue repair. TB-500 is a synthetic fragment of thymosin beta-4.
BPC
Body protection compound, a peptide found in human gastric juice. BPC-157, the form studied in labs, is a 15-amino-acid fragment of it. Almost all of its research is in animals: a 2025 systematic review found 35 preclinical studies and one clinical study, with no clinical safety data, and it is not FDA approved.
Copper peptide
A peptide complexed with a copper ion. GHK-Cu is the canonical copper peptide used for skin and wound healing.
KPV
Lys-Pro-Val. A tripeptide with anti-inflammatory activity, included in the KLOW Combo blend.
Melanocortin
A class of peptide hormones (alpha-MSH, ACTH) that activate melanocortin receptors. PT-141 (bremelanotide) and MT-2 (melanotan-2) are melanocortin agonists.
BDNF
Brain-derived neurotrophic factor. A neuroplasticity protein elevated by some nootropic peptides (e.g., Semax).
VEGF
Vascular endothelial growth factor. A pro-angiogenic signaling protein upregulated by some tissue-repair peptides.
Nitric oxide
A vasodilatory signaling molecule involved in BPC-157's pro-angiogenic activity and in some vasodilator peptide effects.
Collagen synthesis
The cellular process of producing collagen. Upregulated by GHK-Cu and to a lesser extent by BPC-157.
Fibroblast
A connective-tissue cell that produces collagen and other extracellular matrix proteins. Targeted by GHK-Cu.
Incretin
A class of hormones (GLP-1, GIP) that trigger insulin release in response to nutrients. The GLP-1 class drug family is built on incretin biology.

Sources for this section: Seino and colleagues, Journal of Diabetes Investigation 2010 (PMID 24843404); Ozempic prescribing information (DailyMed); Mounjaro prescribing information (DailyMed); Gvoke prescribing information (DailyMed); Omnitrope prescribing information (DailyMed); StatPearls (NCBI Bookshelf), Physiology, Growth Hormone, 2023; MeSH record for BPC 157 (National Library of Medicine); Vasireddi and colleagues, HSS Journal 2025 (PMID 40756949); Jastreboff and colleagues, New England Journal of Medicine 2023 (PMID 37366315).

Chat with us